BMO Capital Initiates Coverage On Sarepta Therapeutics with Outperform Rating, Announces Price Target of $170
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Kostas Biliouris has initiated coverage on Sarepta Therapeutics (NASDAQ:SRPT) with an Outperform rating and set a price target of $170.
January 31, 2024 | 11:07 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BMO Capital has initiated coverage on Sarepta Therapeutics with an Outperform rating and a price target of $170, indicating a positive outlook for the stock.
The initiation of coverage by BMO Capital with an Outperform rating typically suggests a positive outlook on the stock's future performance. The price target of $170 implies a significant potential upside from current levels, which could attract investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100